新華製藥(000756.SZ):華魯投資累計增持414.32萬股A股
格隆匯11月20日丨新華製藥(000756.SZ)公佈,公司於近日收到控股股東華魯控股集團有限公司(“華魯控股”)之全資子公司華魯投資發展有限公司(“華魯投資”)關於增持計劃實施情況的通知。自2019年5月21日至2019年11月20日華魯投資通過深圳證券交易所交易系統購入新華製藥A股約414.32萬股,增持總金額為人民幣約2948.07萬元,佔新華製藥已發行A股的0.97%,佔新華製藥已發行總股份的0.67%。
增持完成以後,華魯控股及其附屬公司合計持有公司股份數量為約2.27億股,約佔公司已發行總股份的 36.47%。此次增持完成後公司仍然滿足上市條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.